Quick Answer
NEKTAR THERAPEUTICS reported Research And Development Expense of $117.33 million for the year ending 2025.
- NEKTAR THERAPEUTICS showed a decrease of -3.0% in Research And Development Expense from 2024 to 2025.
- This data is from NEKTAR THERAPEUTICS's annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), NEKTAR THERAPEUTICS's Research And Development Expense has grown by 23.4%.
- Historical annual values: Fiscal year 2025: $117.33 million | Fiscal year 2024: $120.91 million | Fiscal year 2023: $114.16 million | Fiscal year 2022: $218.32 million | Fiscal year 2021: $400.27 million | Fiscal year 2020: $408.68 million | Fiscal year 2019: $434.57 million | Fiscal year 2018: $399.54 million | Fiscal year 2017: $268.46 million | Fiscal year 2016: $203.80 million | Fiscal year 2015: $182.79 million | Fiscal year 2014: $147.73 million | Fiscal year 2013: $190.01 million | Fiscal year 2012: $148.68 million | Fiscal year 2011: $126.77 million | Fiscal year 2010: $108.07 million | Fiscal year 2009: $95.11 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: